Agreement Signed for Subscription of Shares Aiming to Form a Joint Venture for Alfenax Biologics by Four Companies — Full-Scale Promotion of Domestic Manufacturing Base for Biosimilars —

Background and Key Points of the Partnership

Alfresa Holdings, Mycenax Biotech Inc. (MBI), Kidswell Bio Co., Ltd. and Chiome Bioscience Inc. have signed a share subscription agreement to jointly fund and operate Alfenax Biologics as a joint venture. Payment is scheduled for 2026-11-25, and the contribution ratios are the same as those previously disclosed. The newly established joint venture will develop manufacturing and distribution focused on biopharmaceutical CDMO services on a site in Akita Prefecture. By integrating the strengths of the four companies, the joint venture will strengthen Japan's domestic biopharmaceutical manufacturing base.

Future Schedule and Impact

The share subscription agreement was signed on 2026-11-09, and the payment execution date is scheduled for 2026-11-25. After the four-party joint venture is established, the capital composition will be 45%/45%/7%/3%, and the development of manufacturing and distribution facilities and the start of commercial production are targeted by the fiscal year ending March 2031. This matter is expected to have a minor impact on the Company's results for the fiscal year ending December 2026, and any additional disclosures will be promptly announced.